SCHEMBL3151968

SCHEMBL3151968

Nc1ncc2ncn(CCO)c2n1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.55
ALDH1A1 P00352 1/20 0.55
HPGD P15428 1/20 0.55
ADRA1A P35348 1/20 0.55
HSD17B10 Q99714 1/20 0.55
RXFP1 Q9HBX9 1/20 0.55
HDAC6 Q9UBN7 2/20 0.50
ADORA2A P29274 2/20 0.47
ADORA1 P30542 1/20 0.47
HSP90AA1 P07900 1/20 0.45
HSP90AB1 P08238 1/20 0.45
SYK P43405 1/20 0.40
CCNE1 P24864 3/20 0.37
CDK2 P24941 3/20 0.37
CDK1 P06493 2/20 0.37
CCNB1 P14635 2/20 0.37
TK1 P04183 1/20 0.37
RPS6KA3 P51812 1/20 0.36
LMNA P02545 1/20 0.36
ADORA2B P29275 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8933938 0.85 HSD17B10 (0.52) KDM4EALDH1A1HPGDADRA1AHSD17B10
SCHEMBL6307469 0.84 KDM4E (0.57) KDM4EALDH1A1HPGDADRA1AHSD17B10
SCHEMBL3157542 0.83 HSD17B10 (0.52) KDM4EALDH1A1HPGDADRA1AHSD17B10
SCHEMBL14010824 0.83 KDM4E (0.55) KDM4EALDH1A1HPGDADRA1AHSD17B10
SCHEMBL9116846 0.83 KDM4E (0.53) KDM4EALDH1A1HPGDADRA1AHSD17B10
6-Deoxy Penciclovir SCHEMBL660970 0.83 ALDH1A1 (0.66) KDM4EALDH1A1HPGDADRA1AHSD17B10
6-Deoxy Penciclovir SCHEMBL29797811 0.83 ALDH1A1 (0.66) KDM4EALDH1A1HPGDADRA1AHSD17B10
SCHEMBL10711562 0.83 KDM4E (0.62) KDM4EALDH1A1HPGDADRA1AHSD17B10
SCHEMBL9117042 0.83 KDM4E (0.50) KDM4EALDH1A1HPGDADRA1AHSD17B10
6-Deoxy Penciclovir SCHEMBL3324010 0.82 ALDH1A1 (0.65) KDM4EALDH1A1HPGDADRA1AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101555249-B Method for synthesizing famciclovir ZHEJIANG HISUN PHARM CO LTD 2011-05-11 CN disclosed
EP-1883639-B1 PREPARATION OF FAMCICLOVIR AND OTHER PURINE DERIVATIVES ARROW INT LTD (MT) 2010-09-01 EP disclosed
EP-1636231-B1 METHODS FOR PREPARING 9-[4-ACETOXY-3-(ACETOXYMETHYL)BUT-1-YL]-2-AMINOPURINE USING A COMPOUND OF 2-AMINO-9-(2-SUBSTITUTED ETHYL)PURINES KYUNGDONG PHARM CO LTD (KR) 2010-03-24 EP disclosed
EP-1636231-B1 METHODS FOR PREPARING 9-[4-ACETOXY-3-(ACETOXYMETHYL)BUT-1-YL]-2-AMINOPURINE USING A COMPOUND OF 2-AMINO-9-(2-SUBSTITUTED ETHYL)PURINES KYUNGDONG PHARM CO LTD (KR) 2010-03-24 EP disclosed
CN-101555249-A Method for synthesizing famciclovir ZHEJIANG HISUN PHARMACEUTICAL (CN) 2009-10-14 CN disclosed
US-7601835-B2 Preparation of famciclovir and other purine derivatives ARROW INTERNATIONAL LIMITED (MT) 2009-10-13 US disclosed
US-7601835-B2 Preparation of famciclovir and other purine derivatives ARROW INTERNATIONAL LIMITED (MT) 2009-10-13 US disclosed
CN-100455583-C 2-amino-9- (2-substituted ethyl) purines and methods of using same to prepare 9- [ 4-acetoxy-3- (acetoxymethyl) butan-1-yl ] -2-aminopurine KYUNGDONG PHARM CO LTD (KR) 2009-01-28 CN disclosed
US-7456282-B2 2-amino-9-(2-substituted ethyl)purines and preparing methods for 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine using the same KYUNGDONG PHARM. CO., LTD. (KR) 2008-11-25 US disclosed
US-7456282-B2 2-amino-9-(2-substituted ethyl)purines and preparing methods for 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine using the same KYUNGDONG PHARM. CO., LTD. (KR) 2008-11-25 US disclosed
US-7456282-B2 2-amino-9-(2-substituted ethyl)purines and preparing methods for 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine using the same KYUNGDONG PHARM. CO., LTD. (KR) 2008-11-25 US disclosed
US-20060258862-A1 2-Amino-9-(2-substituted ethyl)purines and preparing methods for 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine using the same KYUNGDONG PHARM. CO., LTD. (KR) 2006-11-16 US disclosed
CN-1791602-A 2-amino-9-(2-substituted ethyl)purines and preparing methods for 9- 4-acetoxy-3-(acetoxymethyl)but-1-yl]- 2- aminopurine using the same KYUNGDONG PHARM CO LTD (KR) 2006-06-21 CN disclosed
EP-1636231-A2 2-AMINO-9-(2-SUBSTITUTED ETHYL)PURINES AND PREPARING METHODS FOR 9- 4-ACETOXY-3-(ACETOXYMETHYL)BUT-1-YL]- 2- AMINOPURINE USING THE SAME Kyungdong Pharm. Co., Ltd. (KR) 2006-03-22 EP disclosed
WO-2004110343-A2 2-AMINO-9-(2-SUBSTITUTED ETHYL)PURINES AND PREPARING METHODS FOR 9-[4-ACETOXY-3-(ACETOXYMETHYL)BUT-1-YL]- 2- AMINOPURINE USING THE SAME KYUNGDONG PHARM. CO., LTD. (KR) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060258862-A1 2-Amino-9-(2-substituted ethyl)purines and preparing methods for 9-[4-acetoxy-3-(acetoxymethyl)but-1-yl]-2-aminopurine using the same TYMP, TPMT, PNP KDM4E 783/4885ALDH1A1 1015/4885HPGD 2021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.